CITATION REPORT List of articles citing

Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer

DOI: 10.1016/j.amjmed.2013.09.015 American Journal of Medicine, 2014, 127, 82-6.e1.

Source: https://exaly.com/paper-pdf/59606242/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
121	Venous thromboembolism in cancer patients: a call for more awareness. 2014 , 21, 163-4		1
120	Prevention and treatment of venous thromboembolism in patients with cancer. 2014 , 2014, 312-7		5
119	The reply. American Journal of Medicine, 2014 , 127, e35	2.4	
118	Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. 2014 , 12, 1746-9		33
117	Thromboprophylaxis in cancer patients. 2014 , 40, 395-400		5
116	Clinical guide SEOM on venous thromboembolism in cancer patients. 2014 , 16, 1079-90		21
115	Evidence-based medicine for thromboprophylaxis in hospitalized patients with cancer: why aren & we there yet?. 2014 , 32, 1754-6		6
114	Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. 2014 , 32, 1792-6		41
113	Thromboprophylaxis in medical inpatients with cancer. American Journal of Medicine, 2014, 127, e11	2.4	3
112	No evidence not to prescribe thromboprophylaxis in hospitalized medical patients with cancer. American Journal of Medicine, 2014 , 127, e33	2.4	1
111	The reply. American Journal of Medicine, 2014 , 127, e13	2.4	
110	Therapy for cancer-related thromboembolism. 2014 , 41, 319-38		19
109	Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants. 2014 , 133 Suppl 2, S167-71		14
108	Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. 2014 , 133 Suppl 2, S122-7		38
107	IMid-based regimens in patients with myeloma. 2014 , 12, 452-3		1
106	Prevenzione della malattia tromboembolica in ambiente medico (non chirurgico). 2015 , 20, 1-7		
105	[Haemostatic aspects in clinical oncology]. 2015 , 35, 152-64; quiz 165		5

(2016-2015)

104	patients. 2015 , 135, 298-302		33
103	Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. 2015 , 22, 133-43		33
102	Novel or non-vitamin K antagonist oral anticoagulants and the treatment of cancer-associated thrombosis. 2015 , 41, 237-43		7
101	[Management of venous thromboembolism in oncological patients: Spanish clinical practice guidelines. Consensus SEACV-SEOM]. 2015 , 144 Suppl 1, 3-15		7
100	[Introduction. Venous thromboembolism in cancer patients]. 2015 , 144 Suppl 1, 1-2		
99	A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness. 2015 , 13, 10		2
98	Management of chemotherapy-induced thromboembolism in breast cancer. 2015 , 4, 187-198		
97	Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH: reply. 2015 , 13, 325-6		3
96	Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study. 2015 , 136, 1145-8		9
95	Prevencia de la enfermedad tromboembaca en contexto no quiragico. 2015 , 41, 1-7		
94	Clinical practice guidelines for prophylaxis of venous thomboembolism in cancer patients. 2016 , 116, 618-25		16
93	. 2016 , 15, 189-196		1
92	Maladie veineuse thromboembolique et cancer. 2016 , 8, 489-496		
91	Quantification of the External Validity of Randomized Controlled Trials Supporting Clinical Care Guidelines: The Case of Thromboprophylaxis. <i>American Journal of Medicine</i> , 2016 , 129, 740-5	·4	1
90	Prophylaxis of venous thromboembolism in cancer patients. 2016 , 9, 535-9		6
89	Cancer-associated thrombosis. 2016 , 62, 121-58		37
88	A critical balance: managing coagulation in patients with glioma. 2016 , 16, 803-14		3
87	Handbook of Thromboprophylaxis. 2016 ,		

Prevention of Venous Thromboembolism. **2016**, 429-443

85	Practice Patterns for Prophylaxis and Treatment of Venous Thromboembolism in German Cancer Patients. 2016 , 39, 194-201	15
84	International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. 2016 , 17, e452-e466	252
83	Quality and Safety in Hospitalized Patients with Cancer. 2016 , 5, 368-378	
82	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 2016 , 37, 2768-2801	1249
81	Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. 2016 , 76, 3671-5	23
80	Thromboprophylaxis in Cancer Patients. 2016 , 97-109	
79	Prophylaxie primaire de la maladie thromboembolique veineuse chez les patients cancfeux ambulatoires trait¶ par les antinBplasiques. 2016 , 18, 23-31	
78	Guidance for the prevention and treatment of cancer-associated venous thromboembolism. 2016 , 41, 81-91	138
77	Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. 2016 , 3, e30-44	33
76	Venous Thromboembolism in Patients Diagnosed With Lung Cancer. 2016 , 67, 709-24	17
75	Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy. 2016 , 76, 331-41	5
74	Cancer and Venous Thromboembolic Disease: A Review. 2017 , 22, 199-207	95
73	Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease. 2017 , 43, 469-478	20
72	Anticoagulation in Cancer Patients. 2017 , 349-352	
71	Cardio-Oncology. 2017 ,	1
70	Vascular Complications of Cancer and Cancer Therapy. 2017 , 215-240	
69	Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study. 2017 , 15, 420-428	22

Manual of Cardio-oncology. 2017, 68 1 Thromboembolic Disorders as a Consequence of Cancer. 2017, 57-74 67 Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis 66 64 of More Than 20'000 Patients. 2017, 6, The challenge of hospital-related thrombosis. 2017, 130, 97-98 65 Association between hospitalization for acute medical illness and VTE risk: A lower efficacy of 64 5 thromboprophylaxis in elderly patients? Results from the EDITH case-control study. 2017, 44, 39-43 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and 63 189 cardiovascular toxicity of the European Society of Cardiology (ESC). 2017, 19, 9-42 62 New paradigms in venous thromboprophylaxis of medically ill patients. 2017, 117, 1662-1670 34 Frequency of venous thromboembolism events during acute inpatient rehabilitation in a 61 3 comprehensive cancer centre. 2017, 49, 758-764 Prophylaxis of Venous Thromboembolism in Geriatric Settings: A Cluster-Randomized 60 3 Multicomponent Interventional Trial. 2018, 19, 497-503 Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary 59 (SEMI-SEOM-SETH) Expert Consensus. 2018, 2, e373-e386 Bleeding and venous thromboembolic events in patients with active cancer hospitalized for an 58 7 acute medical illness. 2018, 169, 44-49 Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients 63 57 with cancer. **2018**, 164 Suppl 1, S112-S118 Risk stratification for the development of venous thromboembolism in hospitalized patients with 56 24 cancer. 2018, 16, 1321-1326 Risks and Benefits of Anticoagulation in Cancer and Noncancer Patients. 2019, 45, 629-637 6 55 Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients 54 with Solid and Hematologic Malignancies. 2019, 3, e153-e156 Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study. 53 31 2019, 6, e79-e88 Thromboprophylaxis for inpatients with advanced cancer in palliative care settings: A systematic 52 2 review and narrative synthesis. 2019, 33, 486-499 [Primary prophylaxis of venous thromboembolism in ambulatory cancer patients treated with 51 antineoplastic agents]. 2019, 40, 523-532

50	Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants. 2019 , 177, 33-41		10
49	Thrombosis and Cancer. 2019, 430-447		
48	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. 2019 , 14, 21-38		8
47	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. 2020 , 38, 496-520		479
46	Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. 2020 , 49, 214-219		4
45	Universal venous thromboembolism policy is effective but may not adequately protect hospitalized cancer patients with larger BMI. 2020 , 49, 113-120		1
44	Management of venous thromboembolism in cancer patients: Considerations about the clinical practice guideline update of the American society of clinical oncology. 2020 , 71, 4-7		4
43	Therapie und Prophylaxe der tumor-assoziierten venßen Thromboembolie. 2020 , 23, 25-30		
42	Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients. 2020 , 7, 571227		1
41	Inpatient prophylaxis in cancer patients: where is the evidence?. 2020 , 191 Suppl 1, S85-S90		1
40	Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer. <i>Cancers</i> , 2020 , 12,	6	3
39	Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels. 2020 , 9, 8062-8073		7
38	Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. 2020 , 4, 2254-2260		9
37	SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). 2020 , 22, 171-186		10
36	Prescribing patterns and outcomes of venous thromboembolism prophylaxis in hospitalized medical and cancer patients: Observations from the Ottawa Hospital. 2021 , 197, 144-152		О
35	Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement. 2021 , 160, 312-321		4
34	Update on Guidelines for the Management of Cancer-Associated Thrombosis. 2021 , 26, e24-e40		28
33	Prediction and Prevention of Cancer-Associated Thromboembolism. 2021 , 26, e2-e7		12

32	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. 2021 , 5, 927-974		96
31	Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. 2021 , 5, 2055-2062		4
30	PhysiciansSOpinions on Anticoagulant Therapy in Patients with a Limited Life Expectancy. 2021 , 47, 735	-744	2
29	Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology	6.6	2
28	New prophylaxis strategies to reduce the risk of thromboembolism in cancer. 2021 , 21, 1135-1144		1
27	Use of antithrombotics at the end of life: an in-depth chart review study. 2021 , 20, 110		О
26	Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma. 2021 , 1		Ο
25	Venous Thromboembolism Prophylaxis in Acute Medically Ill Patients: A Retrospective Cohort Study. <i>American Journal of Medicine</i> , 2020 , 133, 1444-1452.e3	2.4	3
24	Management of cancer-associated venous thromboembolism - a case-based practical approach. 2018 , 47, 77-89		12
23	The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. 2020 , 18, 278-284		13
22	Diagnosis and therapy in cancer-associated thromboembolism I what about guideline recommendations?. <i>Phtbologie</i> , 2015 , 44, 299-303	0.3	1
21	Kardiotoxizitl onkologischer Therapien (3): Komplikationen, Prllention und LangzeitBerwachung.		О
20	Venous thromboembolism in cancer patients: Still looking for answers. <i>Experimental and Therapeutic Medicine</i> , 2019 , 18, 5026-5032	2.1	19
19	Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 258-70	3.4	13
18	VTE risk assessment in cancer. Who needs prophylaxis and who does not?. <i>Phtbologie</i> , 2015 , 35, 319-24	0.3	6
17	Low molecular heparin for cancer-associated venous thromboembolism Litll the LATCH of the day. Ph. Dologie, 2015, 44, 256-260	0.3	
16	Variable support for ASCO recommendations for the prevention and treatment of cancer-associated venous thromboembolism. <i>Phtbologie</i> , 2015 , 44, 320-323	0.3	
15	Analysis of risk factors for venous thromboembolism in patients after thoracic surgery: A clinical study of 167 cases. <i>Turkish Journal of Thoracic and Cardiovascular Surgery</i> , 2018 , 26, 93-98	0.5	

14	[Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?]. <i>Bulletin Du Cancer</i> , 2020 , 107, 224-233	2.4	
13	Prophylaxis of venous thromboembolism disease in patients with cancer. <i>Revista Clinica Espanola</i> , 2020 ,	0.7	О
12	Cancer-associated venous thromboembolism Nature Reviews Disease Primers, 2022, 8, 11	51.1	9
11	Image_1.TIFF. 2020 ,		
10	Table_1.docx. 2020 ,		
9	A Systematic Review of the Guidelines on Venous Thromboembolism Prophylaxis in Gynecologic Oncology. <i>Cancers</i> , 2022 , 14, 2439	6.6	1
8	A review of latest clinical practice guidelines for the management of cancer-associated thrombosis. <i>Best Practice and Research in Clinical Haematology</i> , 2022 , 101348	4.2	О
7	Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps. <i>Best Practice and Research in Clinical Haematology</i> , 2022 , 101347	4.2	
6	Inpatient primary prophylaxis of cancer-associated thromboembolism (CAT). Supportive Care in Cancer,	3.9	
5	Thromboembolic disease prevention before cancer therapy. 2023 , 92-99		
4	Venous thromboembolism and Cancer. 2022 , 439-466		
3	Pediatric cancer-associated thrombosis: Analysis from a tertiary care cancer center in India.		О
2	The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study. 2023 , 07, e14-e29		0
1	Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline 2023,	_	O